AUROPHARMA2020-07-012020-09-30in-bse-fin:OneOperatingExpenses01Member AUROPHARMA2020-07-012020-09-30in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares AUROPHARMA 2020-04-01 2021-03-31 2020-11-02 INR Lakhs Half yearly true Cash Flow Indirect Single segment Pharmaceutical Products 2020-07-01 2020-09-30 Unaudited Standalone 45243400000.00 486200000.00 45729600000.00 18332000000.00 24500000.00 3615100000.00 4266200000.00 64200000.00 1201400000.00 6934200000.00 34437600000.00 11292000000.00 0.00 11292000000.00 3224700000.00 51900000.00 3276600000.00 0.00 8015400000.00 0.00 0.00 0.00 0.00 8015400000.00 -400000.00 8015000000.00 8015000000.00 0.00 585900000.00 1 13.68 13.68 0.00 0.00 13.68 13.68 NOTES:t n1 The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.2 The above standalone financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 11 November 2020. The statutory auditors have carried out limited review of the above results for the quarter and half year ended 30 September 2020. An unmodified report has been issued by them thereon.3 The Company operates in only one segment viz., 'Pharmaceutical Products'. n4 Sales of standalone include exports of Rs.406,508 lakhs for the current quarter (30 September 2019: Rs.266,617 lakhs). 5 The Government of India, on 20 September 2019, vide the Taxation Laws (Amendment) Ordinance 2019, the Ordinance inserted a new Section 115BAA in the Income tax Act, 1961, which provides an option to the Company for paying income tax at reduced rates as per the provisions/conditions defined in the Said section. The Company has evaluated the above Ordinance and based on its evaluation currently the management proposed to continue with the old tax rates.6 The Board in its meeting held on 28 May 2019 approved the scheme of amalgamation of APL Research Centre Limited, Aurozymes Limited, Curepro Parentrals Limited, Hyacinths Pharma Private Limited, Silicon Life Sciences Private Limited and APL Healthcare limited with the Company. The Company has filed an application before the Hon’ble National Company Law Tribunal, Hyderabad Bench (NCLT) on 7 August 2019. The Hon’ble NCLT had passed an order on 30 September 2019 and directed to convene the meetings of Equity Shareholders and Un-secured Creditors of the Company and the Subsidiaries covered under merger scheme, on 30 November 2019. The applicant companies relooked into the business plan of each of entities involved in the amalgamation and accordingly approved to exclude APL Healthcare Limited from the purview of the scheme and filed necessary applications before Hon’ble NCLT for its approval for the exclusion of APL Healthcare Limited, which is pending before the Hon’ble NCLT for hearing. Pending the disposal of the application by NCLT, no adjustments are made in the financial results. n7 Foreign exchange gain includes exchange difference arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of Ind AS 23 on borrowing costs. Single segment 2020-04-01 2020-09-30 Unaudited Standalone 79440400000.00 1742000000.00 81182400000.00 36246300000.00 75900000.00 -193500000.00 8513100000.00 168500000.00 2399300000.00 13078900000.00 60288500000.00 20893900000.00 0.00 20893900000.00 5700500000.00 31200000.00 5731700000.00 0.00 15162200000.00 0.00 0.00 0.00 0.00 15162200000.00 -31700000.00 15130500000.00 15130500000.00 0.00 585900000.00 1 25.88 25.88 0.00 0.00 25.88 25.88 Other Expenses 6934200000.00 Other Expenses 13078900000.00 159900000.00 -3826100000.00 1863300000.00 -252600000.00 -5039200000.00 -2300000.00 0.00 26000000.00 0.00 256500000.00 0.00 1171900000.00 0.00 2399300000.00 -14700000.00 0.00 76000000.00 -22300000.00 0.00 -553100000.00 562400000.00 269400000.00 0.00 -67300000.00 0.00 0.00 0.00 0.00 0.00 -4656500000.00 16237400000.00 0.00 0.00 0.00 2414000000.00 0.00 13823400000.00 0.00 0.00 0.00 4312100000.00 0.00 0.00 0.00 0.00 688900000.00 -727600000.00 0.00 0.00 0.00 208700000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2366100000.00 0.00 0.00 0.00 554800000.00 22000000.00 0.00 0.00 0.00 -4893600000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3267000000.00 45500000.00 0.00 732100000.00 153000000.00 0.00 0.00 -4197600000.00 4732200000.00 -20400000.00 4711800000.00 594300000.00 5306100000.00